×
About 9,283 results

ALLMedicine™ Viral Hepatitis Center

Research & Reviews  2,854 results

Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
https://clinicaltrials.gov/ct2/show/NCT01350648

Feb 3rd, 2023 - Chronic viral hepatitis is a major health problem affecting millions globally. The immunosuppressed population, especially those with HIV infection, remains at particular risk and the incidence of hepatocellular carcinoma (HCC) is increasing in th...

Screening Protocol for the Evaluation of Potential Research Subjects
https://clinicaltrials.gov/ct2/show/NCT01036971

Feb 3rd, 2023 - This protocol describes the screening process used by the National Institute on Drug Abuse (NIDA IRP) to assess potential research participants' eligibility for entering protocols of the NIDA/IRP. Through its clinical research protocols, the IRP a...

Identifying High-Risk Patients With Nonalcoholic Fatty Liver Disease: An Opportunity fo...
https://doi.org/10.1097/MCG.0000000000001784
Journal of Clinical Gastroenterology; No JS, Buckholz A et. al.

Feb 3rd, 2023 - Patients with metabolic syndrome (MetS) are likely to have nonalcoholic fatty liver disease (NAFLD), which can progress to advanced fibrosis. Early recognition of those at highest risk may ameliorate outcomes. Noninvasive liver fibrosis assessment...

Viscoelasticity Imaging to Assess Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT04409340

Feb 1st, 2023 - RESEARCH QUESTION AND BACKGROUND: Primary liver cancer or hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women and is the second cause of cancer mortality worldwide. In Canada, HCC is the only cancer for w...

CT Liver Fat Fraction Quantification
https://clinicaltrials.gov/ct2/show/NCT05676177

Jan 31st, 2023 - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. It affects 25% of the global population, with a higher proportion in Middle Eastern countries, especially in individuals with type 2 diabetes mellitus (T2...

see more →

Guidelines  9 results

Cancer immunotherapy in special challenging populations: recommendations of the Advisor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009216
Journal for Immunotherapy of Cancer; Gonzalez-Cao M, Puertolas T et. al.

Mar 31st, 2021 - Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other t...

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specifi...
https://doi.org/10.1111/jdv.16926
Journal of the European Academy of Dermatology and Venere... Nast A, Smith C et. al.

Feb 7th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

Joint Society statement for elimination of viral hepatitis.
https://doi.org/10.5604/16652681.1226808
Annals of Hepatology; Brahm J, Castera L et. al.

Jan 5th, 2017 - Joint Society statement for elimination of viral hepatitis.|2017|Brahm J,Castera L,Hou J,Lindor K,|standards,diagnosis,mortality,prevention & control,virology,standards,standards,standards,

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidan...
https://doi.org/10.1016/j.jhep.2016.08.002
Journal of Hepatology; Easterbrook PJ,

Sep 20th, 2016 - Testing and diagnosis of hepatitis C virus (HCV) infection is the gateway for access to both treatment and prevention services, and crucial for an effective hepatitis epidemic response. In contrast to HIV, a systematic approach to hepatitis C test...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  255 results

Screening Protocol for the Evaluation of Potential Research Subjects
https://clinicaltrials.gov/ct2/show/NCT01036971

Feb 3rd, 2023 - This protocol describes the screening process used by the National Institute on Drug Abuse (NIDA IRP) to assess potential research participants' eligibility for entering protocols of the NIDA/IRP. Through its clinical research protocols, the IRP a...

Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
https://clinicaltrials.gov/ct2/show/NCT01350648

Feb 3rd, 2023 - Chronic viral hepatitis is a major health problem affecting millions globally. The immunosuppressed population, especially those with HIV infection, remains at particular risk and the incidence of hepatocellular carcinoma (HCC) is increasing in th...

Viscoelasticity Imaging to Assess Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT04409340

Feb 1st, 2023 - RESEARCH QUESTION AND BACKGROUND: Primary liver cancer or hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women and is the second cause of cancer mortality worldwide. In Canada, HCC is the only cancer for w...

Therapeutic Option for Hepatitis B and C: a French Cohort
https://clinicaltrials.gov/ct2/show/NCT01953458

Jan 31st, 2023 - General schedule of the study : Prospective multicenter national study Duration of inclusions:3 years Effective : 25000 patients Duration of the follow-up: 7-8 years Duration of the cohort: 10 years Population : Twenty-five thousands of people wil...

CT Liver Fat Fraction Quantification
https://clinicaltrials.gov/ct2/show/NCT05676177

Jan 31st, 2023 - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. It affects 25% of the global population, with a higher proportion in Middle Eastern countries, especially in individuals with type 2 diabetes mellitus (T2...

see more →

News  566 results

CDC: Mpox Vaccine Is Effective Regardless of Administration Route
https://www.medscape.com/viewarticle/985272

Dec 8th, 2022 - Intradermal administration of the JYNNEOS mpox vaccine is as effective and safe as subcutaneous administration, according to new data released this week by the Centers for Disease Control and Prevention (CDC). Unvaccinated people were nearly 10 ti...

HIV Prevention, Care Showed Resilience During the COVID Pandemic
https://www.medpagetoday.com/hivaids/hivaids/102043

Dec 2nd, 2022 - Drops in HIV testing and pre-exposure prophylaxis (PrEP) prescriptions early on in the pandemic quickly stabilized by the third quarter of 2020, according to a CDC report. The number of HIV tests performed nationally exceeded 2.4 million in the fi...

Hepatitis A
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/285308

For World Hepatitis Day, learn more about the different types of viral hepatitis that impact millions worldwide and what is being done to help eliminate hepatitis.

FDA Rejects Bulevirtide for Hepatitis D
https://www.medscape.com/viewarticle/983305

Oct 31st, 2022 - The US Food and Drug Administration (FDA) has declined to approve bulevirtide, Gilead Sciences' drug for the treatment of hepatitis delta virus (HDV) infection and compensated liver disease. In a complete response letter, the FDA voiced concerns o...

Stigma, Health Discrimination Common for Hispanic Adults With HIV
https://www.medpagetoday.com/hivaids/hivaids/101238

Oct 14th, 2022 - Reports of stigma and healthcare discrimination run high among Hispanic adults with HIV, according to an analysis of self-reported data from the U.S. in 2018 to 2020. Of 2,690 people interviewed, the overall median HIV stigma score was 31.7 on a s...

see more →

Patient Education  23 results see all →